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Abstract
Background: We report a case of recurrent pancreatic cancer that presented as cervical lymphadenopathy.
Case presentation: A 69-year-old woman with stage IIb pancreatic cancer underwent a curative Whipple’s
procedure after neoadjuvant chemoradiation therapy. Despite adjuvant chemotherapy with S-1, postoperative
recurrence was diagnosed as left cervical lymphadenopathy 11 months postoperatively. After she underwent
chemoradiation therapy to the cervical area followed by systemic chemotherapy with S-1, the lymphadenopathy
became unremarkable 17 months postoperatively. S-1 treatment was discontinued 23 months postoperatively at
the patient’s request. She has remained free of disease since that time and has achieved an overall duration of
survival of 48 months.
Conclusions: To the best of our knowledge, this is the first reported case of middle cervical lymph node metastasis
of pancreatic cancer. Although rare, it should be considered as a site of recurrence. This case suggests concurrent
radiation therapy can be a good option for patients who cannot tolerate an aggressive regimen.
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Background
Despite advances in surgical techniques and periopera-
tive care, the probability of long-term survival in patients
with pancreatic adenocarcinoma remains low because of
the high relapse rate. We report a rare case of recurrent
pancreatic cancer that presented as left cervical lymph-
adenopathy. The patient has achieved postoperative sur-
vival of 48 months as a result of multimodal treatment.
Case presentation
A 69-year-old woman presented to our clinic with a
chief complaint of epigastric pain. She had a history of
squamous cell carcinoma of the mandibular gingiva,
which had been completely resected 2 months prior to the
visit (T1N0M0, stage 1). Her laboratory data were normal
except for elevated amylase (327 U/L; upper normal limit
(UNL) <125 IU/L) and DUPAN-2 (16,000 U/mL;
UNL <150 U/mL) levels. Contrast-enhanced computed
tomography (CT) showed a 45-mm low-attenuating
tumor in the head of the pancreas, causing dilatation of
the pancreatic duct and common bile duct (Fig. 1a). CT
further revealed a 24-mm lymph node along the common
hepatic artery (Fig. 1b). No distant metastasis was recog-
nized. An endoscopic ultrasound-guided fine-needle
aspiration biopsy of the lymph node revealed a well-
differentiated tubular adenocarcinoma. Since tumor
invasion to the pancreatic capsule was suspected and the
contour of the superior mesenteric vein (SMV) was
irregular, the clinical stage was Ph, TS3, T4 (CH+,
DU−, S+, RP+, PV+, A−, PL+, OO−), N2M0, cStage
IVb (following the Japan Pancreas Society (JPS) classi-
fication [1]), or T3N1M0, stage IIb (following the
Union for International Cancer Control (UICC) [2]).
The patient received neoadjuvant chemoradiation
therapy (CRT: S-1, 100 mg/day × 28 days + radiation
therapy (RT) 50.4 Gy/28 Fr) for the borderline resectable
pancreatic cancer. After CRT, the DUPAN-2 level de-
creased to 960 U/mL. The tumor shrunk to a diameter
of 18 mm, and the contour between the SMV and the
tumor became clear (Fig. 2). The disease stage following
CRT was TS1, T3 (CH+, DU−, S−, RP−, PV−, A−, PL−,
OO−) N2M0, cStage IVa (JPS), or T1N1M0, stage IIb
(UICC). The patient underwent subtotal stomach-
preserving pancreaticoduodenectomy with D2 dissection
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3 weeks after CRT. Pathological examination revealed
that the primary tumor and the lymph node had become
necrotic, and no residual viable cancer cells were recog-
nized. The pathological diagnosis was invasive ductal
adenocarcinoma, TS1, T1 (CH−, DU−, S−, PV−, A−, PL−,
OO−) N0M0, pStage I (JPS), or T1N0M0, stage I (UICC),
and R0 resection was confirmed. Gemcitabine was discon-
tinued after two courses because of grade 3 neutropenia,
and the patient therefore received S-1 (80 mg/day) for
6 months as adjuvant chemotherapy.
Four months after the discontinuation of S-1
(11 months postoperatively), CT revealed adenopathy of
a left accessory nerve lymph node and deep cervical
lymph nodes. Further, positron-emission tomography
(PET)-CT revealed an abnormal accumulation at these
lymph nodes (Fig. 3). The DUPAN-2 level was elevated
to 4460 U/mL. Aspiration biopsy of the lymph nodes re-
vealed adenocarcinoma with an immunohistochemical
pattern that was compatible with the preceding pancre-
atic cancer; thus, postoperative recurrence was con-
firmed. S-1 therapy (80 mg/day) was restarted and
concurrent RT (50.4 Gy/28 Fr) to the cervical area was
adopted for local control. The lymphadenopathy became
unremarkable on a CT scan obtained 17 months postop-
eratively (Fig. 4), and the DUPAN-2 level decreased to
normal. S-1 treatment was discontinued 23 months
postoperatively at the patient’s request. She has been
disease free since that time and has achieved an overall
survival of 48 months.
Discussion
We present a rare case of recurrent pancreatic cancer, in
which recurrence presented as left cervical lymphaden-
opathy, and the patient achieved an overall survival of
48 months. Considering that the median postoperative
survival time for stage IVb (JPS) pancreatic cancer is
only 11.7 months [3], this case is remarkable.
Postoperative recurrences of pancreatic cancer can be
categorized as either local recurrence or distant metasta-
sis. Common sites of the latter include the liver, periton-
eum, para-aortic lymph nodes, and lung [4]. To date,
about ten cases of cervical lymph node metastasis have
been reported [5–7] but in all of these cases, metastasis
was noted in the supraclavicular lymph nodes. To the
best of our knowledge, this is the first reported case of
middle cervical lymph node metastasis of pancreatic
cancer. Generally, pancreatic cancer is known to
metastasize rapidly to the lymphatic system. The exact
mechanism of the spread has not been elucidated, but it
is probably caused by permeation, embolization, and
Fig. 1 CT showing the primary tumor (a; arrow) and a swollen lymph node (b; arrowhead)
Fig. 2 CT images after chemoradiation therapy (a, b)
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retrograde spread due to lymphatic obstruction in the
pancreas [7]. The route of metastasis to the middle cer-
vical lymph node is not clear, but provided that the can-
cer cells spread through the mediastinal lymph nodes to
the supraclavicular lymph node, they can cause middle
lymph node metastasis along the way. Cervical lymph
node metastases can be overlooked because CT scans
performed during normal postoperative follow-up often
omit the cervical area, and PET-CT scans are not rou-
tinely performed.
In our case, the most likely differential diagnosis of
cervical lymphadenopathy should be metastasis of man-
dibular gingival squamous cell carcinoma because as
much as 7 % of such cases can involve postoperative
lymph node metastasis [8], even in cases of T1 stage
disease. However, this possibility was ruled out by exam-
ination of the lymph node biopsy specimen, which
revealed adenocarcinoma. Another possibility was me-
tastasis of occult adenocarcinoma. The alternative was
also unlikely in our case because esophagogastroduode-
noscopy and CT ruled out the presence of any other pri-
mary lesion, and the immunohistochemical profile of the
lymph node was consistent with the primary pancreatic
cancer.
While the Japanese clinical guidelines for pancreatic
cancer lump recurrent disease with metastatic or unre-
sectable disease [9], the National Comprehensive Cancer
Network guidelines propose specific treatment strategies
for postoperative recurrence [10]. For distant metastasis
that occurs less than 6 months after the completion of
primary therapy, the guidelines recommend enrollment
of the patient in a clinical trial and list alternative sys-
temic chemotherapy and best supportive care as options.
In the present case, however, re-administration of S-1
was the only choice because our patient could not toler-
ate gemcitabine.
S-1 has been the key drug for treating pancreatic can-
cer since the JASPAC-01 study revealed its superiority to
gemcitabine in the adjuvant chemotherapy setting in
Japan [11]. We chose to add concurrent radiation for
local control in order to intensify the antitumor activity.
In principle, RT for recurrent disease is limited to local
recurrence and palliative care, while distant metastasis
should be treated as a systemic disease. In practice, how-
ever, aggressive chemotherapy is often a difficult choice
for fragile patients with recurrent pancreatic cancer. We
expect that the effects of S-1 contributed greatly to the
good outcome in our patient; yet, at the same time, this
case implies that concurrent RT is a potent option for
localized distant metastasis.
Conclusions
We have described a rare case in which recurrent pan-
creatic cancer presented as left cervical lymphadenop-
athy in a patient who achieved an overall survival of
48 months.
Fig. 3 Adenopathy of a left accessory nerve lymph node (a; arrow) and middle deep cervical lymph nodes (b; arrowhead)
Fig. 4 CT after chemoradiation therapy showing complete response to the treatment (a, b)
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Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Abbreviation
CRT: chemoradiation therapy; CT: computed tomography; JPS: Japan
Pancreas Society; SMV: superior mesenteric vein; UICC: Union for
International Cancer Control.
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